This biopharmaceutical company develops oral immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway for cancer treatment. They aim to provide more affordable and accessible oral immunotherapy options, particularly for non-small cell lung cancer and underserved regions.
Funding
Funding not disclosed
Founders
Product
Problem
Access to cancer immunotherapy, specifically immune checkpoint inhibitors, is limited in many regions due to the high cost and logistical challenges associated with traditional antibody-based therapies. This disparity prevents numerous patients, particularly those in low- and middle-income countries, from receiving potentially life-saving treatments. The need for infusion centers and complex supply chains further exacerbates these accessibility issues.
Solution
OmRx Oncology is developing OX-4224, an oral small molecule checkpoint inhibitor targeting the PD-1/PD-L1 pathway, to expand global access to cancer immunotherapy. OX-4224 offers a more affordable and accessible alternative to traditional antibody therapies, eliminating the need for infusion centers and simplifying supply chain logistics. The oral formulation allows for flexible dosing schedules and easier administration, making it a scalable solution for resource-constrained settings. OmRx Oncology is initially focusing on developing OX-4224 as a monotherapy for non-small cell lung cancer (NSCLC) in low- and middle-income countries, with the potential to expand globally for all-oral combination therapies. A Phase 2 clinical trial is underway to evaluate the safety and efficacy of OX-4224 in patients with metastatic NSCLC whose tumors express PD-L1.
Target Audience
The primary target audience includes patients with solid tumors, particularly non-small cell lung cancer (NSCLC), in low- and middle-income countries where access to traditional antibody-based immunotherapies is limited, as well as clinical researchers and medical professionals focused on expanding access to cancer care.
Features
- Oral small molecule targeting the PD-1/PD-L1 immune checkpoint pathway
- Designed for monotherapy and potential all-oral combination therapies
- Simplified logistics, eliminating the need for infusion centers
- Flexible dosing schedules for improved patient convenience
- Phase 2 clinical trials underway evaluating safety and efficacy in NSCLC